Research programme: pluripotent stem cell therapy - Cynata Therapeutics

Drug Profile

Research programme: pluripotent stem cell therapy - Cynata Therapeutics

Alternative Names: Cymerus™ MSC

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cynata Therapeutics
  • Developer Cynata Therapeutics; Monash University
  • Class Antiasthmatics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Asthma

Most Recent Events

  • 23 Aug 2017 Preclinical trials in Asthma in Australia (Intranasal)
  • 23 Aug 2017 Pharmacodynamics data from a preclinical trial in Asthma released by Cynata Therapeutics
  • 23 Aug 2017 Cynata Therapeutics plans clinical trials (Combination therapy) for Asthma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top